Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 34.99M |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.92% | -1.57% | +48.70% | +84.37% | 55.92B | |
| +0.93% | +7.22% | +64.67% | +63.56% | 56.67B | |
| -2.15% | -2.12% | -21.84% | -16.34% | 23.28B | |
| +0.17% | -1.39% | +3.18% | +422.07% | 23.28B | |
| -0.36% | -0.56% | +36.00% | -3.93% | 20.54B | |
| -1.34% | +0.51% | +25.02% | -30.27% | 17.78B | |
| -1.44% | -1.63% | +37.07% | +589.93% | 15.9B | |
| -1.30% | -9.92% | +160.67% | +284.37% | 14.64B | |
| +0.33% | -0.82% | +23.82% | +178.83% | 13.99B | |
| Average | -0.94% | +0.47% | +41.92% | +174.73% | 26.89B | |
| Weighted average by Cap. | -0.81% | +1.47% | +43.03% | +137.15% |
